212 related articles for article (PubMed ID: 33099392)
21. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis.
Coronel-Pérez IM; Rodríguez-Rey EM; Camacho-Martínez FM
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):481-5. PubMed ID: 20028444
[TBL] [Abstract][Full Text] [Related]
22. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows.
Faghihi G; Andalib F; Asilian A
Eur J Dermatol; 2009; 19(6):586-7. PubMed ID: 19620039
[TBL] [Abstract][Full Text] [Related]
24. The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial.
Rafati M; Mahmoudian R; Golpour M; Kazeminejad A; Saeedi M; Nekoukar Z
Dermatol Ther; 2022 Jun; 35(6):e15450. PubMed ID: 35289043
[TBL] [Abstract][Full Text] [Related]
25. A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Immunotherapy; 2023 Oct; 15(14):1093-1103. PubMed ID: 37403610
[TBL] [Abstract][Full Text] [Related]
26. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
Piraccini BM; Ohyama M; Craiglow B; Bewley A; Ding Y; Chen YF; Dutronc Y; Pierce E; Durand F; Mostaghimi A
J Dermatolog Treat; 2023 Dec; 34(1):2227299. PubMed ID: 37381691
[TBL] [Abstract][Full Text] [Related]
27. Alopecia Areata Progression Index, a Scoring System for Evaluating Overall Hair Loss Activity in Alopecia Areata Patients with Pigmented Hair: A Development and Reliability Assessment.
Jang YH; Moon SY; Lee WJ; Lee SJ; Lee WK; Park BC; Kim H; Kim DW
Dermatology; 2016; 232(2):143-9. PubMed ID: 26757319
[TBL] [Abstract][Full Text] [Related]
28. Isolated eyebrow and eyelash trichotillomania mimicking alopecia areata.
Radmanesh M; Shafiei S; Naderi AH
Int J Dermatol; 2006 May; 45(5):557-60. PubMed ID: 16700791
[TBL] [Abstract][Full Text] [Related]
29. Multiple courses of pulse corticosteroid therapy for alopecia areata.
Yoshimasu T; Kanazawa N; Yamamoto Y; Furukawa F
J Dermatol; 2016 Sep; 43(9):1075-7. PubMed ID: 27095016
[TBL] [Abstract][Full Text] [Related]
30. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl.
Zímová J; Zímová P
Acta Dermatovenerol Croat; 2016 Jun; 24(2):150-3. PubMed ID: 27477178
[TBL] [Abstract][Full Text] [Related]
31. Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.
Hon KL; Luk DCK; Leung AKC; Ng C; Loo SKF
Recent Pat Inflamm Allergy Drug Discov; 2020; 14(2):117-132. PubMed ID: 32723274
[TBL] [Abstract][Full Text] [Related]
32. Five-year experience in the treatment of alopecia areata with DPC.
El-Zawahry BM; Bassiouny DA; Khella A; Zaki NS
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):264-9. PubMed ID: 19744175
[TBL] [Abstract][Full Text] [Related]
33. Videodermatoscopy enhances diagnostic capability in some forms of hair loss.
Lacarrubba F; Dall'Oglio F; Rita Nasca M; Micali G
Am J Clin Dermatol; 2004; 5(3):205-8. PubMed ID: 15186200
[TBL] [Abstract][Full Text] [Related]
34. Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.
Thaçi D; Tziotzios C; Ito T; Ko J; Karadağ AS; Fang H; Edwards RA; Bonfanti G; Wolk R; Tran H; Law E
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2621-2634. PubMed ID: 37707764
[TBL] [Abstract][Full Text] [Related]
35. Eyelash alopecia areata: case series and literature review.
Modjtahedi BS; Kishan AU; Schwab IR; Jackson WB; Maibach HI
Can J Ophthalmol; 2012 Aug; 47(4):333-8. PubMed ID: 22883840
[TBL] [Abstract][Full Text] [Related]
36. Congenital alopecia areata.
Lenane P; Pope E; Krafchik B
J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):8-11. PubMed ID: 15692503
[TBL] [Abstract][Full Text] [Related]
37. Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse alopecia areata that has a favorable prognosis.
Sato-Kawamura M; Aiba S; Tagami H
Dermatology; 2002; 205(4):367-73. PubMed ID: 12444333
[TBL] [Abstract][Full Text] [Related]
38. Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study.
Zaher H; Gawdat HI; Hegazy RA; Hassan M
Dermatology; 2015; 230(4):308-13. PubMed ID: 25765294
[TBL] [Abstract][Full Text] [Related]
39. Diffuse alopecia areata is associated with intense inflammatory infiltration and CD8+ T cells in hair loss regions and an increase in serum IgE level.
Zhao Y; Zhang B; Caulloo S; Chen X; Li Y; Zhang X
Indian J Dermatol Venereol Leprol; 2012; 78(6):709-14. PubMed ID: 23075639
[TBL] [Abstract][Full Text] [Related]
40. Treatment of alopecia areata: An Australian expert consensus statement.
Cranwell WC; Lai VW; Photiou L; Meah N; Wall D; Rathnayake D; Joseph S; Chitreddy V; Gunatheesan S; Sindhu K; Sharma P; Green J; Eisman S; Yip L; Jones L; Sinclair R
Australas J Dermatol; 2019 May; 60(2):163-170. PubMed ID: 30411329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
